➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Express Scripts

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 6,552,065

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 6,552,065 protect, and when does it expire?

Patent 6,552,065 protects FARYDAK and is included in one NDA.

This patent has forty-six patent family members in thirty-three countries.

Summary for Patent: 6,552,065
Title: Deacetylase inhibitors
Abstract:The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.
Inventor(s): Remiszewski; Stacy William (Washington Township, NJ), Bair; Kenneth Walter (Mountain Lakes, NJ), Versace; Richard William (Wanaque, NJ), Perez; Lawrence Blas (Hackettstown, NJ), Green; Michael Alan (Easton, PA), Sambucetti; Lidia Cristina (Pacifica, CA), Sharma; Sushil (West Orange, NJ)
Assignee: Novartis AG (Basel, CH)
Application Number:09/944,275
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 6,552,065

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-001 Feb 23, 2015 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-002 Feb 23, 2015 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Secura FARYDAK panobinostat lactate CAPSULE;ORAL 205353-003 Feb 23, 2015 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,552,065

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 035057 ⤷  Free Forever Trial
Austria 376999 ⤷  Free Forever Trial
Australia 2001282129 ⤷  Free Forever Trial
Australia 8212901 ⤷  Free Forever Trial
Brazil 0113669 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.